Metastatic pancreatic cancer has historically been one of the most difficult cancers to treat. Once pancreatic cancer has spread to distant organs, treatment generally focuses on controlling disease, extending survival and maintaining quality of life rather than achieving a cure. The five year relative survival rate for distant pancreatic cancer remains approximately 3%, highlighting the urgent need for more effective therapies. To read more visit here: https://www.tumblr.com/careset....publications/8289119

Pancreatic cancer has long presented one of the most difficult challenges in oncology. In the United States, an estimated 67,530 new pancreatic cancer cases and 52,740 deaths are expected in 2026. The five-year relative survival rate remains only 13.7%, while patients diagnosed with distant disease have a five-year relative survival of just 3.4%. To read more visit here:https://careset.livepositively.....com/healthy-living/

Onivyde (irinotecan liposome injection) has become an important treatment option in the management of metastatic pancreatic adenocarcinoma. Unlike clinical trials, which evaluate treatment under controlled conditions, Medicare claims data can provide a broader view of how a therapy is being used in routine healthcare settings. Examining these data can reveal utilisation patterns, treatment settings and changes in demand over time. Read more: https://medium.com/@careset/wh....at-medicare-claims-d

For patients with previously treated metastatic pancreatic cancer, treatment options have historically offered limited benefit. The results of the phase 3 RASolute 302 trial have now introduced a significant shift, showing that daraxonrasib can substantially extend survival compared with standard chemotherapy. Read more. https://caresetsystems.livejou....rnal.com/417.html?ne

For decades, pancreatic cancer has remained one of the most difficult cancers to treat. The disease is often diagnosed at an advanced stage, while available treatments for metastatic pancreatic ductal adenocarcinoma (mPDAC) have historically provided limited survival benefits. But the results of the Phase 3 RASolute 302 trial could mark an important change in how advanced pancreatic cancer is treated. Read more. https://www.patreon.com/CareSe....t/posts/what-rasolut